Summary

• The Trump administration’s recent cuts at the FDA have put the agency’s executive capacity under strain, which may lead to medicine shortages and less innovation.
• Marty Makary’s successor as the new FDA commissioner thus faces a tough task.
• The FDA’s ability to balance speed with safety helps explain why the US has a more innovative pharmaceutical sector than Europe.

By Diederik Stadig, Senior Economist, Healthcare & Technology

Executive summary

Marty Makary, the US Food and Drug Administration (FDA) commissioner, has been ousted just over a year into the role amid criticism from both inside and outside the

5.41K Followers